Table 3.

Risk of Parkinson’s disease associated with increasing number of minor alleles of the ESR1 and ESR2 polymorphisms in women.

	PMH Status	Cases (n)	Controls (n)	Adj RR (95% CI)1	Int with Caff*	Int with PMH@
ESR1
	All	38/75/40	215/305/183	1.07 (0.84, 1.36)	0.47	0.53
9	Ever Users	24/50/26	124/186/115	1.03 (0.75, 1.42)
RS2077647	Never Users	8/20/10	69/86/41	1.26 (0.74, 2.13)
	All	103/44/5	458/215/24	1.01 (0.73, 1.40)	0.66	0.74
10	Ever Users	68/28/4	270/137/16	0.93 (0.62, 1.39)
RS2228480	Never Users	23/13/1	126/62/7	1.16 (0.59, 2.27)
	All	44/67/43	187/343/178	1.05 (0.82, 1.34)	0.07	0.58
11	Ever Users	30/44/26	110/215/105	1.04 (0.76, 1.43)
RS3798577	Never Users	7/16/15	51/88/58	1.31 (0.79, 2.16)
ESR2
	All	143/10/0	644/58/0	0.70 (0.34, 1.44)	0.26	0.03
4	Ever Users	97/4/0	386/41/0	0.35 (0.12, 1.05)
RS1256049	Never Users	30/6/0	181/12/0	2.00 (0.63, 6.36)
	All	47/78/29	217/352/140	0.99 (0.77, 1.28)	0.10	0.37
12	Ever Users	32/52/17	129/213/88	0.88 (0.64, 1.20)
RS1256030	Never Users	12/17/8	62/99/34	1.25 (0.75, 2.09)
	All	50/79/23	243/337/122	1.02 (0.79, 1.32)	0.48	0.28
13	Ever Users	34/52/14	142/204/78	0.88 (0.64, 1.21)
RS928554	Never Users	11/19/6	72/93/32	1.38 (0.81, 2.33)
	All	126/29/2	545/154/9	0.81 (0.54, 1.22)	0.07	0.68
14	Ever Users	86/14/2	332/92/3	0.72 (0.41, 1.24)
RS1255998	Never Users	29/10/0	154/41/3	0.88 (0.37, 2.11)
	All	50/80/23	235/331/117	1.02 (0.78, 1.32)	0.58	0.20
15	Ever Users	34/53/13	140/200/74	0.88 (0.64, 1.22)
RS1152579	Never Users	11/19/7	69/92/31	1.47 (0.88, 2.45)

^*Caffeine modeled as a linear variable in mg/day

^@PMH modeled as dichotomous (never/ever users)

¹adjusted for matching factors (age, source of DNA (blood or buccal smear), race) with additional adjustment for smoking in pack years Analyses among ever and never users of PMH included an additional interaction term between smoking and use of PMH